

Summary

Preface	1
Introduction	3
Healthcare Dilemma.....	3
Opportunity Cost.....	4
Efficiency and Equity	5
HTA and Pharmacoeconomics	7
Pharmacoeconomics	11
Sensitivity Analysis.....	13
Summary.....	14
Questions	15
Answers	16
References and Further Readings.....	17
1 Principles of Epidemiology	19
1.1 Introduction	19
1.2 Study Design	20
Non-Experimental Studies	20
Experimental Studies.....	24
Non-Randomized Studies	31
Systematic and Narrative Reviews	32
1.3 Bias in Epidemiology	33
Selection Bias	34
Information Bias.....	35
Confounding.....	36
1.4 Measures of Occurrence	37
Incidence.....	37
Prevalence.....	38
1.5 Measures of Association	39
Contingency Tables	39
Relative Risk	39
Risk Difference	41
Odds Ratio.....	42
Hazard Ratio.....	43

1.6	Regressions: How to Interpret Results	43
	Univariate Linear Regression Model	44
	Multivariate Linear Regression Model.....	46
	Questions	48
	Answers	49
	References.....	50
2	Definitions and Basic Concepts	53
2.1	Definitions	53
2.2	Costs	54
2.3	Consequences	56
	Economic Outcomes.....	56
	Patient Outcomes.....	56
2.4	Perspectives	58
2.5	Time Horizon	58
	Discounting.....	59
	Questions	61
	Answers	62
	References.....	63
3	Pharmacoeconomic Evaluations	65
3.1	Introduction	65
3.2	Cost Analysis	66
	Cost of Care.....	66
3.3	Cost-Outcomes Analysis	67
	Cost-Effectiveness.....	67
3.4	Multicriteria Decision Analysis	70
	Example: MCDA in Communicable e Non-Communicable Disease	71
	Cost-Utility.....	73
	Cost-Minimization.....	73
	Cost-Benefit	73
	Cost-Consequence Analysis	74
3.5	Utility	74
3.6	Psychometrics	75
	Questions	78
	Answers	81
	References.....	82

4	Modeling Frameworks	85
4.1	Introduction.....	86
4.2	Microsimulation or Cohort Modeling?.....	87
	Example: Microsimulation Model in HIV.....	88
4.3	Steps in Decision Analysis.....	89
	Example: How to Develop a Model for Emergency Contraception and Pregnancy?... 89	
	Problem Conceptualization.....	89
	Model Conceptualization.....	90
	Model Parameter Estimation.....	92
	Run the Model and Interpretation.....	93
	Sensitivity Analysis, Transparency, and Validation.....	95
4.4	Markov Models.....	96
	Example: Markov Model in the Treatment of Secondary Hyperparathyroidism.....	97
4.5	Partitioned Survival Models.....	100
	Example: PSM in Advanced or Unresectable Hepatocellular Carcinoma.....	100
4.6	Discrete-Event Simulation.....	103
	Example: DES Model in TPN.....	103
4.7	Discretely Integrated Condition Event Simulation.....	106
	Example: How to Develop a DICE Model in Cancer.....	107
4.8	Agent-Based Models.....	108
	Example: AB Model in Screening Program.....	109
4.9	Conclusions.....	110
	Questions.....	112
	Answers.....	114
	References.....	115
5	Budget Impact Analysis	119
5.1	Introduction.....	119
5.2	Example: Budget Impact Analysis of Apixaban to Treat and Prevent Venous Thromboembolism in Italy.....	122
	Questions.....	126
	Answers.....	126
	References.....	127
6	Patient Reported Outcomes	129
6.1	From Physiological Measures to Patient Reported Outcome.....	130

6.2	Quality of Life, Health-Related Quality of Life, and Patient Reported Outcomes	131
	Quality of Life.....	131
	Health-Related Quality of Life.....	132
	Patient Reported Outcomes.....	133
6.3	Individual Health and Circumstantial Perceptions and Experiences	134
6.4	Applications of PRO Instruments	136
6.5	Identifying an Appropriate Instrument for Measuring PRO	138
6.6	When are the Results of PROs Relevant?	141
6.7	Summary and Conclusion	142
	Questions.....	143
	Answers.....	144
	References.....	145
7	Data Sources and Accounting for Uncertainty	153
7.1	Data Sources	153
	Clinical Epidemiology.....	154
	Literature Analysis.....	155
	Clinical Studies.....	161
	Administrative Databases.....	161
	Financial Data.....	164
7.2	Statistical Analysis	164
7.3	Accounting for Uncertainty	166
	Definition of Error.....	166
	Principal Sources of Error in Clinical Studies.....	166
	Reducing Error in Clinical Studies.....	167
	Selection Bias in Subjects Entering the Study.....	167
	Selection Bias in Subjects After Entering the Study.....	170
7.4	Pharmacoeconomic Studies	170
	Sensitivity Analysis.....	170
7.5	Conclusions: Evaluating Pharmacoeconomic Studies	177
	Questions.....	178
	Answers.....	181
	References.....	182
	Glossary	187
	Authors	193